Trial Profile
Phosphodiesterase Type 5 Inhibition With Tadalafil Changes Outcomes in Heart Failure: Extent of Renal Damage (PITCH-ER)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 26 Jul 2023
Price :
$35
*
At a glance
- Drugs Tadalafil (Primary)
- Indications Acute kidney injury; Heart failure; Pulmonary hypertension
- Focus Pharmacodynamics; Therapeutic Use
- Acronyms PITCH-ER
- 27 Jun 2014 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
- 18 Oct 2013 New trial record